Dear Colleagues,

Mortality rates from cancer have declined over the past three decades largely due to early detection strategies and advances in cancer therapeutics. However, the improvement of cancer survivorship often comes with an increased risk of cardiovascular morbidity and mortality. Cardio-oncology, a new interdisciplinary discipline, ames to address the complexity of intersection and interplay of cardiovascular diseases and cancer. Several types of anti-cancer treatments have been associated with potential cardiovascular toxicity. An example is anthracycline exposure which may lead to potentially irreversible cardiac dysfunction. Myocarditis induced by immune checkpoint inhibitors has now emerged as a new challenge in clinical care. Proteasome inhibitors and a plethora of other targeted cancer therapies have been reported to potentially cause cardiovascular toxicity. It is of great importance to investigate the mechanisms of cancer treatment-related cardiovascular complications as well as their prevention and therapeutic strategies.

This special issue requests submissions about cardiovascular toxicity associated with anticancer treatment. We welcome original research and review articles from cardiologists, oncologists, pharmacists and other investigators.

Potential topics include but are not limited to the following:
• An overview of cardiovascular toxicity related to novel anticancer treatments.
• Determining the best method for cardiac monitoring such as electrocardiogram, echocardiogram and cardiac biomarkers.
• Assessing the potential mechanisms and pathophysiology of cardiovascular toxicity associated with cancer treatments.
• Prevention and treatment strategies for anticancer related cardiovascular toxicity.
• Identification of shared mechanisms along with common risk factors related to cancer and cardiovascular diseases.

Prof. Tong Liu, Ying Liu and Leilei Cheng
Guest Editors